Canada Markets open in 6 hrs 55 mins

Pluristem Therapeutics Inc. (PJT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.27850.0000 (0.00%)
As of 09:08AM CEST. Market open.
Full screen
Previous Close1.2785
Open1.2785
Bid1.2740 x N/A
Ask1.4085 x N/A
Day's Range1.2785 - 1.2785
52 Week Range1.2230 - 3.5710
Volume100
Avg. Volume5
Market Cap43.472M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.5720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.92
  • GlobeNewswire

    Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

    Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pl

  • GlobeNewswire

    Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

    Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiat

  • GlobeNewswire

    Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

    Eyal Rosenthal (photo credit Jim Vetter) Eyal Rosenthal, CEO of Tnuva and Pluristem's new joint venture. Photographed by Jim Vetter. HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufact